Our assay can help predict the likelihood your candidate has of inducing cytokine release syndrome
Want to learn more about our Cytokine Release model?
Contact one of our team now to see how we can help
CRS or cytokine storm, is a broad term to describe uncontrolled cytokine release in response to an administered product, and is a severe and sometimes fatal, side-effect of a number of immunomodulatory monoclonal antibodies and cell therapy treatments.
Screening at an early stage in the discovery process using our in vitro cytokine release assay will enable you to reduce the immunotoxicity of your candidates by informed rational design.
CRS can result from binding to non-target immune cells or even prolonged binding to the intended target which can elicit an exaggerated effect.
Find other methods of assessing the tumour microenvironment
Cytokine Release assays?
In a results-driven manner, our expert immunologists can work with you to develop further immunological assays to interrogate the data arising from the cytokine release assay.
Check out some of the technologies we use for Cytokine Release assays
Our cytokine release assays can help you predict some of the immunotoxicities which may be associated with your candidate. Our expert immunologists will work closely with you to ensure that we offer you the most appropriate assay set up for your therapeutic candidates.
T CELL MEDIATED
Stay in touch with our R&D in this space and request further info